TPST
Tempest TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that TPST-2003 has unusually strong early efficacy and tolerability signals for a micro-cap platform story, with manufacturing-transfer milestones, a planned U.S. registrational path later in 2026, and a separate partner-funded China BLA path planned for 2027 providing multiple routes to re-rate if execution stays on track [#SEC-8K-2026-05-14] [#SEC-8K-2026-03-30].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Financing remains central because the March 2026 update described only $2 million upfront in the private placement, with additional proceeds dependent on warrant exercise [#SEC-8K-2026-03-30].
Momentum
85
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $2.40 · Bear $0.35
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $11.00
Why
Momentum85 · Δ7d -
Value41 · Δ7d -0.1
Sentiment61 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
85
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
61
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 85.3 / Value 41.1 / Sentiment 60.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$15.44M
Beta
-2.45
Shares Out
15.98M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.19
Rev YoY
-100.0%
EPS YoY
-19.8%
Gross Margin
-351.1%
Op Margin
-
Net Debt
$434K
Current Ratio
0.74
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology